ROSS LEVINE, MD

Ross Levine, MD

Ross Levine, MD, is a physician scientist and Member of the Human Oncology and Pathogenics Program and an Attending Physician on the Leukemia Service, Department of Medicine, the Laurence Joseph Dineen Chair in Leukemia Research and the director of the MSK Center for Hematologic Malignancies. Dr. Levine received his AB from Harvard College and a M.D. from Johns Hopkins.  Dr. Levine served as a Resident in Internal Medicine at the MGH and subsequently as a Hematology-Oncology Fellow at DFCI. He then joined Gary Gilliland’s laboratory as a postdoctoral fellow and performed kinome sequencing at the Broad Institute to identify JAK2V617F and MPL mutations in MPN patients. In September 2007, he was recruited to MSK to the Human Oncology and Pathogenesis Program while he sees patients on the Leukemia Service.

The focus of Dr. Levine’s work is to improve our understanding of the genetic basis of myeloid malignancies, with a specific focus on the role of oncogenic disease alleles in the pathogenesis of myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML).  Dr. Levine’s current efforts are focused on the following areas:

• Role of mutations in epigenetic modifiers in MPN and AML pathogenesis and therapeutic response.
• Investigation of the role of different signaling pathways in hematopoietic transformation
• Characterization of targeted therapies in MPN/AML patients using in vitro and in vivo assays, and elucidation of the mechanisms of resistance to these therapies.